{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:55:27Z","timestamp":1792612527010,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40618-021-01691-5","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T08:30:41Z","timestamp":1634632241000},"page":"583-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial"],"prefix":"10.1007","volume":"45","clinical-trial-number":[{"clinical-trial-number":"isrctn13199265","registry":"10.18810\/isrctn"}],"author":[{"given":"V.","family":"Soldat-Stankovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Popovi\u0107-Peji\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stankovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Male\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bjeki\u0107-Macut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Livadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ognjanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mastorakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mici\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6731-8596","authenticated-orcid":false,"given":"D.","family":"Macut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"1691_CR1","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-14-0253","volume":"171","author":"G Conway","year":"2014","unstructured":"Conway G, Dewailly D, Diamanti-Kandarakis E et al (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1-29. https:\/\/doi.org\/10.1530\/EJE-14-0253","journal-title":"Eur J Endocrinol"},{"key":"1691_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.steroids.2017.12.009","volume":"130","author":"B Echibur\u00fa","year":"2018","unstructured":"Echibur\u00fa B, P\u00e9rez-Bravo F, Galgani JE et al (2018) Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. Steroids 130:15\u201321. https:\/\/doi.org\/10.1016\/j.steroids.2017.12.009","journal-title":"Steroids"},{"key":"1691_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.mce.2012.10.010","volume":"373","author":"TM Barber","year":"2013","unstructured":"Barber TM, Franks S (2013) Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol 373:68\u201376. https:\/\/doi.org\/10.1016\/j.mce.2012.10.010","journal-title":"Mol Cell Endocrinol"},{"key":"1691_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/humrep\/der418","volume":"27","author":"D Panidis","year":"2012","unstructured":"Panidis D, Tziomalos K, Misichronis G et al (2012) Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 27:541\u2013549. https:\/\/doi.org\/10.1093\/humrep\/der418","journal-title":"Hum Reprod"},{"key":"1691_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","volume":"257","author":"Y Arita","year":"1999","unstructured":"Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79\u201383. https:\/\/doi.org\/10.1006\/bbrc.1999.0255","journal-title":"Biochem Biophys Res Commun"},{"key":"1691_CR6","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00125-006-0419-9","volume":"49","author":"BK Tan","year":"2006","unstructured":"Tan BK, Chen J, Digby JE et al (2006) Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia 49:2723\u20132728. https:\/\/doi.org\/10.1007\/s00125-006-0419-9","journal-title":"Diabetologia"},{"key":"1691_CR7","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/humrep\/del146","volume":"21","author":"HF Escobar-Morreale","year":"2006","unstructured":"Escobar-Morreale HF, Villuendas G, Botella-Carretero JI et al (2006) Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 21:2257\u20132265. https:\/\/doi.org\/10.1093\/humrep\/del146","journal-title":"Hum Reprod"},{"key":"1691_CR8","doi-asserted-by":"publisher","first-page":"R219","DOI":"10.1530\/REP-14-0435","volume":"149","author":"PM Spritzer","year":"2015","unstructured":"Spritzer PM, Lecke SB, Satler F, Morsch DM (2015) Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 149:R219-227. https:\/\/doi.org\/10.1530\/REP-14-0435","journal-title":"Reproduction"},{"key":"1691_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.0.1380269","volume":"138","author":"E Diamanti-Kandarakis","year":"1998","unstructured":"Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A (1998) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138:269\u2013274. https:\/\/doi.org\/10.1530\/eje.0.1380269","journal-title":"Eur J Endocrinol"},{"key":"1691_CR10","doi-asserted-by":"publisher","first-page":"CD003053","DOI":"10.1002\/14651858.CD003053.pub6","volume":"11","author":"LC Morley","year":"2017","unstructured":"Morley LC, Tang T, Yasmin E et al (2017) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 11:CD003053. https:\/\/doi.org\/10.1002\/14651858.CD003053.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"1691_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-09-0733","volume":"162","author":"E Diamanti-Kandarakis","year":"2010","unstructured":"Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 162:193\u2013212. https:\/\/doi.org\/10.1530\/EJE-09-0733","journal-title":"Eur J Endocrinol"},{"key":"1691_CR12","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/jog.12101","volume":"39","author":"HO Hamed","year":"2013","unstructured":"Hamed HO (2013) Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. J Obstet Gynaecol Res 39:1596\u20131603. https:\/\/doi.org\/10.1111\/jog.12101","journal-title":"J Obstet Gynaecol Res"},{"key":"1691_CR13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.fertnstert.2009.06.034","volume":"92","author":"A Karkanaki","year":"2009","unstructured":"Karkanaki A, Piouka A, Katsikis I et al (2009) Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. Fertil Steril 92:2078\u20132081. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.06.034","journal-title":"Fertil Steril"},{"key":"1691_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40618-016-0523-8","volume":"40","author":"K Polak","year":"2017","unstructured":"Polak K, Czyzyk A, Simoncini T, Meczekalski B (2017) New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 40:1\u20138. https:\/\/doi.org\/10.1007\/s40618-016-0523-8","journal-title":"J Endocrinol Invest"},{"key":"1691_CR15","doi-asserted-by":"publisher","first-page":"1968450","DOI":"10.1155\/2018\/1968450","volume":"2018","author":"A Bevilacqua","year":"2018","unstructured":"Bevilacqua A, Bizzarri M (2018) Inositols in insulin signaling and glucose metabolism. Int J Endocrinol 2018:1968450. https:\/\/doi.org\/10.1155\/2018\/1968450","journal-title":"Int J Endocrinol"},{"key":"1691_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2337\/diacare.29.02.06.dc05-1070","volume":"29","author":"J-P Baillargeon","year":"2006","unstructured":"Baillargeon J-P, Diamanti-Kandarakis E, Ostlund RE et al (2006) Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 29:300\u2013305. https:\/\/doi.org\/10.2337\/diacare.29.02.06.dc05-1070","journal-title":"Diabetes Care"},{"key":"1691_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/653561","volume":"2014","author":"R D\u2019Anna","year":"2014","unstructured":"D\u2019Anna R, Santamaria A, Cannata ML et al (2014) Effects of a new flavonoid and Myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: a randomized trial. Int J Endocrinol 2014:653561. https:\/\/doi.org\/10.1155\/2014\/653561","journal-title":"Int J Endocrinol"},{"key":"1691_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41\u201347. https:\/\/doi.org\/10.1093\/humrep\/deh098","journal-title":"Hum Reprod"},{"key":"1691_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/humupd\/dmr042","volume":"18","author":"HF Escobar-Morreale","year":"2012","unstructured":"Escobar-Morreale HF, Carmina E, Dewailly D et al (2012) Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 18:146\u2013170. https:\/\/doi.org\/10.1093\/humupd\/dmr042","journal-title":"Hum Reprod Update"},{"key":"1691_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/812610","volume":"2015","author":"D Macut","year":"2015","unstructured":"Macut D, Ba\u010devi\u0107 M, Bo\u017ei\u0107-Anti\u0107 I et al (2015) Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol 2015:812610. https:\/\/doi.org\/10.1155\/2015\/812610","journal-title":"Int J Endocrinol"},{"key":"1691_CR21","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1001\/archinte.168.19.2146","volume":"168","author":"MR Sowers","year":"2008","unstructured":"Sowers MR, Randolph J, Jannausch M et al (2008) Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the \u201ctiming hypothesis.\u201d Arch Intern Med 168:2146\u20132153. https:\/\/doi.org\/10.1001\/archinte.168.19.2146","journal-title":"Arch Intern Med"},{"key":"1691_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.29252\/ijrm.15.7.423","volume":"15","author":"B Namavar Jahromi","year":"2017","unstructured":"Namavar Jahromi B, Dabaghmanesh MH, Parsanezhad ME, Fatehpoor F (2017) Association of leptin and insulin resistance in PCOS: a case-controlled study. Int J Reprod Biomed 15:423\u2013428","journal-title":"Int J Reprod Biomed"},{"key":"1691_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmv025","volume":"21","author":"N Naderpoor","year":"2015","unstructured":"Naderpoor N, Shorakae S, de Courten B et al (2015) Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update 21:560\u2013574. https:\/\/doi.org\/10.1093\/humupd\/dmv025","journal-title":"Hum Reprod Update"},{"key":"1691_CR24","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1210\/jcem.85.8.6738","volume":"85","author":"R Pasquali","year":"2000","unstructured":"Pasquali R, Gambineri A, Biscotti D et al (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767\u20132774. https:\/\/doi.org\/10.1210\/jcem.85.8.6738","journal-title":"J Clin Endocrinol Metab"},{"key":"1691_CR25","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.26355\/eurrev_201903_17278","volume":"23","author":"M Le Donne","year":"2019","unstructured":"Le Donne M, Metro D, Alibrandi A et al (2019) Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 23:2293\u20132301. https:\/\/doi.org\/10.26355\/eurrev_201903_17278","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1691_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jnutbio.2012.01.008","volume":"24","author":"ML Croze","year":"2013","unstructured":"Croze ML, Vella RE, Pillon NJ et al (2013) Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. J Nutr Biochem 24:457\u2013466. https:\/\/doi.org\/10.1016\/j.jnutbio.2012.01.008","journal-title":"J Nutr Biochem"},{"key":"1691_CR27","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.2337\/diabetes.51.10.2951","volume":"51","author":"I Gabriely","year":"2002","unstructured":"Gabriely I, Ma XH, Yang XM et al (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51:2951\u20132958. https:\/\/doi.org\/10.2337\/diabetes.51.10.2951","journal-title":"Diabetes"},{"key":"1691_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejogrb.2010.08.022","volume":"154","author":"M Olszanecka-Glinianowicz","year":"2011","unstructured":"Olszanecka-Glinianowicz M, Kuglin D, D\u0105bkowska-Hu\u0107 A, Ska\u0142ba P (2011) Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 154:51\u201356. https:\/\/doi.org\/10.1016\/j.ejogrb.2010.08.022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1691_CR29","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.fertnstert.2011.02.041","volume":"95","author":"SB Lecke","year":"2011","unstructured":"Lecke SB, Mattei F, Morsch DM, Spritzer PM (2011) Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril 95:2044\u20132049. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.02.041","journal-title":"Fertil Steril"},{"key":"1691_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000324582","volume":"4","author":"A Zulian","year":"2011","unstructured":"Zulian A, Cancello R, Girola A et al (2011) In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts 4:27\u201333. https:\/\/doi.org\/10.1159\/000324582","journal-title":"Obes Facts"},{"key":"1691_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/dom.12021","volume":"15","author":"J Gagnon","year":"2013","unstructured":"Gagnon J, Sheppard E, Anini Y (2013) Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes Metab 15:276\u2013279. https:\/\/doi.org\/10.1111\/dom.12021","journal-title":"Diabetes Obes Metab"},{"key":"1691_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000053002","volume":"53","author":"J Vrb\u00edkov\u00e1","year":"2002","unstructured":"Vrb\u00edkov\u00e1 J, Hill M, St\u00e1rka L, Vondra K (2002) Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. Gynecol Obstet Invest 53:100\u2013104. https:\/\/doi.org\/10.1159\/000053002","journal-title":"Gynecol Obstet Invest"},{"key":"1691_CR33","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1093\/humrep\/dem271","volume":"22","author":"B Trolle","year":"2007","unstructured":"Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF (2007) Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 22:2967\u20132973. https:\/\/doi.org\/10.1093\/humrep\/dem271","journal-title":"Hum Reprod"},{"key":"1691_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/cen.13304","volume":"86","author":"V Tagliaferri","year":"2017","unstructured":"Tagliaferri V, Romualdi D, Immediata V et al (2017) Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol 86:725\u2013730. https:\/\/doi.org\/10.1111\/cen.13304","journal-title":"Clin Endocrinol"},{"key":"1691_CR35","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1210\/jcem.82.12.4431","volume":"82","author":"JE Nestler","year":"1997","unstructured":"Nestler JE, Jakubowicz DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82:4075\u20134079. https:\/\/doi.org\/10.1210\/jcem.82.12.4431","journal-title":"J Clin Endocrinol Metab"},{"key":"1691_CR36","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1210\/en.2012-1145","volume":"153","author":"A Hirsch","year":"2012","unstructured":"Hirsch A, Hahn D, Kempn\u00e1 P et al (2012) Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology 153:4354\u20134366. https:\/\/doi.org\/10.1210\/en.2012-1145","journal-title":"Endocrinology"},{"key":"1691_CR37","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/s0015-0282(99)00407-0","volume":"72","author":"A la Marca","year":"1999","unstructured":"la Marca A, Morgante G, Paglia T et al (1999) Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 72:985\u2013989. https:\/\/doi.org\/10.1016\/s0015-0282(99)00407-0","journal-title":"Fertil Steril"},{"key":"1691_CR38","doi-asserted-by":"publisher","first-page":"8145","DOI":"10.1038\/srep08145","volume":"5","author":"K Cho","year":"2015","unstructured":"Cho K, Chung JY, Cho SK et al (2015) Antihyperglycemic mechanism of metformin occurs via the AMPK\/LXR\u03b1\/POMC pathway. Sci Rep 5:8145. https:\/\/doi.org\/10.1038\/srep08145","journal-title":"Sci Rep"},{"key":"1691_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/eje.0.1440619","volume":"144","author":"J Vrb\u00edkov\u00e1","year":"2001","unstructured":"Vrb\u00edkov\u00e1 J, Hill M, St\u00e1rka L et al (2001) The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol 144:619\u2013628. https:\/\/doi.org\/10.1530\/eje.0.1440619","journal-title":"Eur J Endocrinol"},{"key":"1691_CR40","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3109\/09513590.2012.685205","volume":"28","author":"AD Genazzani","year":"2012","unstructured":"Genazzani AD, Prati A, Santagni S et al (2012) Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 28:969\u2013973. https:\/\/doi.org\/10.3109\/09513590.2012.685205","journal-title":"Gynecol Endocrinol"},{"key":"1691_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/09513590.2012.743020","volume":"29","author":"PG Artini","year":"2013","unstructured":"Artini PG, Di Berardino OM, Papini F et al (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 29:375\u2013379. https:\/\/doi.org\/10.3109\/09513590.2012.743020","journal-title":"Gynecol Endocrinol"},{"key":"1691_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5603\/GP.2019.0002","volume":"90","author":"M Januszewski","year":"2019","unstructured":"Januszewski M, Issat T, Jakimiuk AA et al (2019) Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol 90:7\u201310. https:\/\/doi.org\/10.5603\/GP.2019.0002","journal-title":"Ginekol Pol"},{"key":"1691_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/09513590.2015.1054802","volume":"31","author":"JE Nestler","year":"2015","unstructured":"Nestler JE, Unfer V (2015) Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol 31:501\u2013505. https:\/\/doi.org\/10.3109\/09513590.2015.1054802","journal-title":"Gynecol Endocrinol"},{"key":"1691_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/s0015-0282(98)00011-9","volume":"69","author":"LC Morin-Papunen","year":"1998","unstructured":"Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK (1998) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69:691\u2013696. https:\/\/doi.org\/10.1016\/s0015-0282(98)00011-9","journal-title":"Fertil Steril"},{"key":"1691_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/jcem.85.1.6293","volume":"85","author":"P Moghetti","year":"2000","unstructured":"Moghetti P, Castello R, Negri C et al (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139\u2013146. https:\/\/doi.org\/10.1210\/jcem.85.1.6293","journal-title":"J Clin Endocrinol Metab"},{"key":"1691_CR46","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1210\/jc.2013-4021","volume":"99","author":"CT Pau","year":"2014","unstructured":"Pau CT, Keefe C, Duran J, Welt CK (2014) Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab 99:1870\u20131878. https:\/\/doi.org\/10.1210\/jc.2013-4021","journal-title":"J Clin Endocrinol Metab"},{"key":"1691_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2337\/dc14-1480","volume":"38","author":"M Hansen","year":"2015","unstructured":"Hansen M, Pals\u00f8e MK, Helge JW, Dela F (2015) The effect of metformin on glucose homeostasis during moderate exercise. Diabetes Care 38:293\u2013301. https:\/\/doi.org\/10.2337\/dc14-1480","journal-title":"Diabetes Care"},{"key":"1691_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3109\/09513590.2012.736563","volume":"29","author":"AD Nascimento","year":"2013","unstructured":"Nascimento AD, Silva Lara LA, de S\u00e1 J, Rosa-e-Silva AC et al (2013) Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol 29:246\u2013249. https:\/\/doi.org\/10.3109\/09513590.2012.736563","journal-title":"Gynecol Endocrinol"},{"key":"1691_CR49","first-page":"85","volume":"66","author":"O Grigoryan","year":"2014","unstructured":"Grigoryan O, Absatarova J, Andreeva E et al (2014) Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women. Minerva Ginecol 66:85\u201389","journal-title":"Minerva Ginecol"},{"issue":"Suppl 2","key":"1691_CR50","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.fertnstert.2005.04.043","volume":"84","author":"B Sonntag","year":"2005","unstructured":"Sonntag B, G\u00f6tte M, W\u00fclfing P et al (2005) Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 84(Suppl 2):1173\u20131179. https:\/\/doi.org\/10.1016\/j.fertnstert.2005.04.043","journal-title":"Fertil Steril"},{"key":"1691_CR51","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.fertnstert.2009.01.114","volume":"93","author":"D Romualdi","year":"2010","unstructured":"Romualdi D, Giuliani M, Cristello F et al (2010) Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 93:2303\u20132310. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.01.114","journal-title":"Fertil Steril"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01691-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T10:39:46Z","timestamp":1699699186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01691-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01691-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"2 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was obtained from the Ethics Committee of University Clinical Center of the Republic of Srpska (01-9-742.2\/16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures performed in human participants were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki Declaration and its later amendments of ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Written informed consent was obtained from all individual human participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}